San Carlos – October 12, 2026 -- Noah Medical has completed its first commercial procedure in Asia with the Galaxy System at Prince of Wales Hospital in Hong Kong, moving the robotic bronchoscopy platform from clinical study to routine hospital use in the region.
Hong Kong hospital moves Galaxy from clinical study to commercial use
The hospital performed the first clinical use of the platform in Asia in December 2023. The new procedure marks the transition from clinical investigation to commercial integration, according to the company.
Thoracic surgeon Dr. Calvin S. H. Ng, a Professor at the Chinese University of Hong Kong and Consultant Thoracic Surgeon at Prince of Wales Hospital, performed the procedure. Dr. Ng took part in early development of the Galaxy System, and the company says his input shaped its design.
Embedded imaging is the platform's differentiator, Noah Medical says
Noah Medical describes Galaxy as the only robotic-assisted bronchoscopy platform on the market with embedded imaging. The company says the design allows real-time targeting of tools and lesions in a single-platform workflow while minimizing radiation exposure.
Dr. Ng said adopting the system into routine practice reflects confidence in its real-world applicability. He added that it supports consistent, safe outcomes and fits the hospital's long-term strategy for minimally invasive lung diagnostics and therapy.
US volume tops 16,000 procedures as Asia-Pacific push begins
Noah Medical reports more than 16,000 procedures performed in the United States. The company calls the Hong Kong case a strategic step in its long-term commitment to the Asia-Pacific region.
Founder and CEO Jian Zhang, PhD, said the milestone underscores a focus on "long-term, scalable partnerships." The release gives no pricing, installed-base figures or further Asian rollout targets.